DNA prime-protein boost strategy with replicase-based DNA vaccine against foot-and-mouth disease in bovine calves

Veterinary Microbiology

Volumn 163, Issue 1-2, 2013, Pages 62-70

  Dar, Pervaiz A ^a   Suryanaryana, Veluvarthy S ^a   Nagarajan, G ^b   Reddy, Golla R ^a   Dechamma, Hosur J ^a   Kondabattula, Ganesh ^a  

^a INDIAN VETERINARY RESEARCH INSTITUTE   (India)

^b NATIONAL RESEARCH CENTRE ON CAMEL   (India)

Author keywords

Cattle; Foot and mouth disease; Immune response; Multivalent epitope vaccine; Prime boost vaccination regime; Replicase based DNA vaccine

Indexed keywords

DNA VACCINE; EPITOPE; GAMMA INTERFERON; NEUTRALIZING ANTIBODY; PSINCMV VAC MEG990; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; COW; CYTOKINE PRODUCTION; FOOT AND MOUTH DISEASE; GENE EXPRESSION; IMMUNE RESPONSE; NONHUMAN; PROVOCATION TEST; SINDBIS VIRUS; VACCINATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CATTLE; CELL LINE; CRICETINAE; DNA-DIRECTED DNA POLYMERASE; EPITOPES; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; INTERFERON-GAMMA; MALE; VACCINATION; VACCINES, DNA; VIRAL VACCINES;

ANIMALIA; BOS; BOVINAE; FOOT-AND-MOUTH DISEASE VIRUS; SINDBIS VIRUS;

EID: 84874558411     PISSN: 03781135     EISSN: 18732542     Source Type: Journal    
DOI: 10.1016/j.vetmic.2012.12.017     Document Type: Article

References (64)

1. Albert M.L., Pearce S.F., Francisco L.M., Sauter B., Roy P., Silverstein R.L., Bhardwaj N. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 1998, 188:1359-1368.
2. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413:732-738.
3. Barnett P.V., Keel P., Reid S., Armstrong R.M., Statham R.J., Voyce C., Aggarwal N., Cox S.J. Evidence that high potency foot-and-mouth disease vaccine inhibits local virus replication and prevents the " carrier" state in sheep. Vaccine 2004, 22:1221-1232.
4. Baxter R., Craigmile S.C., Haley C., Douglas A.J., Williams J.L., Glass E.J. BoLA-DR peptide binding pockets are fundamental for foot-and-mouth disease virus vaccine design in cattle. Vaccine 2009, 28:28-37.
5. Beard C., Ward G., Rieder E., Chinsangaram J., Grubman M.J., Mason P.W. Development of DNA vaccines for foot-and-mouth disease, evaluation of vaccines encoding replicating and non-replicating nucleic acids in swine. J. Biotechnol. 1999, 73:243-249.
6. Berglund P., Smerdou C., Fleeton M.N., Tubulekas I., Liljestrom P. Enhancing immune responses using suicidal DNA vaccines. Nat. Biotechnol. 1998, 16:562-565.
7. Bittle J.L., Houghten R.A., Alexander H., Shinnick T.M., Sutcliffe J.G., Lerner R.A., Rowlands D.J., Brown F. Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature 1982, 298:30-33.
8. Castelli J.C., Hassel B.A., Wood K.A., Li X.L., Amemiya K., Dalakas M.C., Torrence P.F., Youle R.J. A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system. J. Exp. Med. 1997, 186:967-972.
9. Chinsangaram J., Beard C., Mason P.W., Zellner M.K., Ward G., Grubman M.J. Antibody response in mice inoculated with DNA expressing foot-and-mouth disease virus capsid proteins. J. Virol. 1998, 72:4454-4457.
10. Cox S.J., Voyce C., Parida S., Reid S.M., Hamblin P.A., Hutchings G., Paton D.J., Barnett P.V. Effect of emergency FMD vaccine antigen payload on protection, sub-clinical infection and persistence following direct contact challenge of cattle. Vaccine 2006, 24:3184-3190.
11. Crowe S.R., Turner S.J., Miller S.C., Roberts A.D., Rappolo R.A., Doherty P.C., Ely K.H., Woodland D.L. Differential antigen presentation regulates the changing patterns of CD8+ T cell immunodominance in primary and secondary influenza virus infections. J. Exp. Med. 2003, 198:399-410.
12. Dar P.A., Ganesh K., Nagarajan G., Sarika S., Reddy G.R., Suryanarayana V.V. Sindbis virus replicase-based DNA vaccine construct encoding FMDV-specific multivalent epitope gene: studies on its immune responses in guinea pigs. Scand. J. Immunol. 2012, 76:345-353.
13. Der S.D., Yang Y.L., Weissmann C., Williams B.R. A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:3279-3283.
14. Deshpande M.S., Ambagala T.C., Hegde N.R., Hariharan M.J., Navaratnam M., Srikumaran S. Induction of cytotoxic T-lymphocytes specific for bovine herpesvirus-1 by DNA immunization. Vaccine 2002, 20:3744-3751.
15. DiMarchi R., Brooke G., Gale C., Cracknell V., Doel T., Mowat N. Protection of cattle against foot-and-mouth disease by a synthetic peptide. Science 1986, 232:639-641.
16. Doel T.R., Gale C., Brooke G., DiMarchi R. Immunization against foot-and-mouth disease with synthetic peptides representing the C-terminal region of VP1. J. Gen. Virol. 1988, 69(Pt 9):2403-2406.
17. Domingo E., Escarmis C., Baranowski E., Ruiz-Jarabo C.M., Carrillo E., Nunez J.I., Sobrino F. Evolution of foot-and-mouth disease virus. Virus Res. 2003, 91:47-63.
18. Domingo E., Escarmis C., Martinez M.A., Martinez-Salas E., Mateu M.G. Foot-and-mouth disease virus populations are quasispecies. Curr. Top. Microbiol. Immunol. 1992, 176:33-47.
19. Dory D., Remond M., Beven V., Cariolet R., Zientara S., Jestin A. Foot-and-mouth disease virus neutralizing antibodies production induced by pcDNA3 and Sindbis virus based plasmid encoding FMDV P1-2A3C3D in swine. Antiviral Res. 2009, 83:45-52.
20. Glass E.J., Millar P. Induction of effective cross-reactive immunity by FMDV peptides is critically dependent upon specific MHC-peptide-T cell interactions. Immunology 1994, 82:1-8.
21. Goris N., Willems T., Diev V.I., Merkelbach-Peters P., Vanbinst T., Van der Stede Y., Kraft H.P., Zakharov V.M., Borisov V.V., Nauwynck H.J., Haas B., De Clercq K. Indirect foot-and-mouth disease vaccine potency testing based on a serological alternative. Vaccine 2008, 26:3870-3879.
22. Grubman M.J., Baxt B. Foot-and-mouth disease. Clin. Microbiol. Rev. 2004, 17:465-493.
23. Hanke T., Neumann V.C., Blanchard T.J., Sweeney P., Hill A.V., Smith G.L., McMichael A. Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine 1999, 17:589-596.
24. Hariharan M.J., Driver D.A., Townsend K., Brumm D., Polo J.M., Belli B.A., Catton D.J., Hsu D., Mittelstaedt D., McCormack J.E., Karavodin L., Dubensky T.W., Chang S.M., Banks T.A. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J. Virol. 1998, 72:950-958.
25. Haupt K., Roggendorf M., Mann K. The potential of DNA vaccination against tumor-associated antigens for antitumor therapy. Exp. Biol. Med. 2002, 227:227-237.
26. Hingley P.J., Pay T.W. Sources of variability in foot and mouth disease vaccine potency estimates based on serum neutralizing antibody assay. J. Biol. Stand. 1987, 15:127-142.
27. Huang H., Yang Z., Xu Q., Sheng Z., Xie Y., Yan W., You Y., Sun L., Zheng Z. Recombinant fusion protein and DNA vaccines against foot and mouth disease virus infection in guinea pig and swine. Viral Immunol. 1999, 12:1-8.
28. Jin H., Kang Y., Xiao C., Zhu K., Ma Y., Xie Q., Ma J., Xie Q., He C., Yang Z., Sun Z., Zhang X., Chen M., Zhang F., Wang B. DNA prime followed by protein boost enhances neutralization and Th1 type immunity against FMDV. Viral Immunol. 2005, 18:539-548.
29. Kamrud K.I., Hooper J.W., Elgh F., Schmaljohn C.S. Comparison of the protective efficacy of naked DNA, DNA-based Sindbis replicon, and packaged Sindbis replicon vectors expressing Hantavirus structural genes in hamsters. Virology 1999, 263:209-219.
30. Kirman J.R., Turon T., Su H., Li A., Kraus C., Polo J.M., Belisle J., Morris S., Seder R.A. Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. Infect. Immun. 2003, 71:575-579.
31. Kitching R.P., Knowles N.J., Samuel A.R., Donaldson A.I. Development of foot-and-mouth disease virus strain characterisation-a review. Trop. Anim. Health Prod. 1989, 21:153-166.
32. Leitner W.W., Hwang L.N., Bergmann-Leitner E.S., Finkelstein S.E., Frank S., Restifo N.P. Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. Vaccine 2004, 22:1537-1544.
33. Leitner W.W., Hwang L.N., deVeer M.J., Zhou A., Silverman R.H., Williams B.R., Dubensky T.W., Ying H., Restifo N.P. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat. Med. 2003, 9:33-39.
34. Leitner W.W., Ying H., Driver D.A., Dubensky T.W., Restifo N.P. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res. 2000, 60:51-55.
35. Leitner W.W., Ying H., Restifo N.P. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 1999, 18:765-777.
36. Li Y., Stirling C.M., Denyer M.S., Hamblin P., Hutchings G., Takamatsu H.H., Barnett P.V. Dramatic improvement in FMD DNA vaccine efficacy and cross-serotype antibody induction in pigs following a protein boost. Vaccine 2008, 26:2647-2656.
37. Ljungberg K., Whitmore A.C., Fluet M.E., Moran T.P., Shabman R.S., Collier M.L., Kraus A.A., Thompson J.M., Montefiori D.C., Beard C., Johnston R.E. Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine. J. Virol. 2007, 81:13412-13423.
38. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
39. Mahapatra M., Hamblin P., Paton D.J. Foot-and-mouth disease virus epitope dominance in the antibody response of vaccinated animals. J. Gen. Virol. 2012, 93:488-493.
40. McCullough K.C., Bruckner L., Schaffner R., Fraefel W., Muller H.K., Kihm U. Relationship between the anti-FMD virus antibody reaction as measured by different assays, and protection in vivo against challenge infection. Vet. Microbiol. 1992, 30:99-112.
41. Nagarajan G., Kumar C.A., Dechamma H.J., Reddy G.R., Ganesh K. Cloning and expression of FMDV-VP1 immunoreactive peptide in trivalent form and its application as immunogen. Indian J. Biotechnol. 2008, 7:472-477.
42. Oh Y., Fleming L., Statham B., Hamblin P., Barnett P., Paton D.J., Park J.H., Joo Y.S., Parida S. Interferon-gamma induced by in vitro re-stimulation of CD4+ T-cells correlates with in vivo FMD vaccine induced protection of cattle against disease and persistent infection. PloS one 2012, 7. e44365.
43. Parida S., Oh Y., Reid S.M., Cox S.J., Statham R.J., Mahapatra M., Anderson J., Barnett P.V., Charleston B., Paton D.J. Interferon-gamma production in vitro from whole blood of foot-and-mouth disease virus (FMDV) vaccinated and infected cattle after incubation with inactivated FMDV. Vaccine 2006, 24:964-969.
44. Pay T.W., Hingley P.J. A potency test method for foot and mouth disease vaccine based on the serum neutralizing antibody response produced in cattle. Vaccine 1992, 10:707-713.
45. Perry B.D., Rich K.M. Poverty impacts of foot-and-mouth disease and the poverty reduction implications of its control. Vet. Rec. 2007, 160:238-241.
46. Quetglas J.I., Ruiz-Guillen M., Aranda A., Casales E., Bezunartea J., Smerdou C. Alphavirus vectors for cancer therapy. Virus Res. 2010, 153:179-196.
47. Ramshaw I.A., Ramsay A.J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today 2000, 21:163-165.
48. Ratish G., Viswanathan S., Suryanarayana V.V. C-terminal region of VP1 of selected foot-and-mouth disease virus serotypes: expression in E. coli and affinity purification. Acta Virol. 1999, 43:205-211.
49. Reed L.J., Reed L.J. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938, 27:493-497.
50. Reid S.M., Ferris N.P., Hutchings G.H., Samuel A.R., Knowles N.J. Primary diagnosis of foot-and-mouth disease by reverse transcription polymerase chain reaction. J. Virol. Methods 2000, 89:167-176.
51. Rodriguez L.L., Gay C.G. Development of vaccines toward the global control and eradication of foot-and-mouth disease. Expert Rev. Vaccines 2011, 10:377-387.
52. Rodriguez L.L., Grubman M.J. Foot and mouth disease virus vaccines. Vaccine 2009, 27(Suppl. 4):D90-D94.
53. Sabarth N., Howard M.K., Savidis-dacho H., Maurik A.V., Barrett P.N., Kistner O. Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model. Update 2010, 28:650-656.
54. Seder R.A., Hill A.V. Vaccines against intracellular infections requiring cellular immunity. Nature 2000, 406:793-798.
55. Shieh J.J., Liang C.M., Chen C.Y., Lee F., Jong M.H., Lai S.S., Liang S.M. Enhancement of the immunity to foot-and-mouth disease virus by DNA priming and protein boosting immunization. Vaccine 2001, 19:4002-4010.
56. Suryanarayana V.V., Viswanathan S., Ratish G., Bist P., Prabhudas K., Gajendragad M.R., Natarajan C. E. coli expressed proteins as diagnostic reagents for typing of foot-and-mouth disease virus. Arch. Virol. 1999, 144:1701-1712.
57. Taboga O., Tami C., Carrillo E., Nunez J.I., Rodriguez A., Saiz J.C., Blanco E., Valero M.L., Roig X., Camarero J.A., Andreu D., Mateu M.G., Giralt E., Domingo E., Sobrino F., Palma E.L. A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants. J. Virol. 1997, 71:2606-2614.
58. Vaine M., Wang S., Hackett A., Arthos J., Lu S. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 2010, 28:2999-3007.
59. Ward G., Rieder E., Mason P.W. Plasmid DNA encoding replicating foot-and-mouth disease virus genomes induces antiviral immune responses in swine. J. Virol. 1997, 71:7442-7447.
60. Wong H.T., Cheng S.C., Chan E.W., Sheng Z.T., Yan W.Y., Zheng Z.X., Xie Y. Plasmids encoding foot-and-mouth disease virus VP1 epitopes elicited immune responses in mice and swine and protected swine against viral infection. Virology 2000, 278:27-35.
61. Wu H.P., Kuo S.F., Wu S.Y., Chuang D.Y. High interleukin-12 production from stimulated peripheral blood mononuclear cells of type 2 diabetes patients. Cytokine 2010, 51:298-304.
62. Ying H., Zaks T.Z., Wang R.F., Irvine K.R., Kammula U.S., Marincola F.M., Leitner W.W., Restifo N.P. Cancer therapy using a self-replicating RNA vaccine. Nat. Med. 1999, 5:823-827.
63. Yu X., Xiao S., Fang L., Jiang Y., Chen H. Enhanced immunogenicity to food-and-mouth disease virus in mice vaccination with alphaviral replicon-based DNA vaccine expressing the capsid precursor polypeptide (P1). Virus Genes 2006, 33:337-344.
64. Zhong W., Marshall D., Coleclough C., Woodland D.L. CD4+ T cell priming accelerates the clearance of Sendai virus in mice, but has a negative effect on CD8+ T cell memory. J. Immunol. 2000, 164:3274-3282.